Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of C. difficile Vaccine in Healthy Japanese Adults
NCT02725437Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Clostridium difficile vaccine in Clostridioides difficile infection (CDI) (6 arms), sponsored by Pfizer. Primary endpoints: Proportions of subjects reporting local reactions, Proportions of subjects reporting systemic events and 3 more. Started Feb 2016; status: completed.
02
Drugs
Clostridium difficile vaccine
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02725437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725437.